Mrna-3927 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 245 | Propionic acidemia | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003529-36-GB (EUCTR) | 18/12/2020 | 03/03/2020 | A clinical study to evaluate the medicinal product in Patients with Propionic Acidemia | A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia | Propionic Acidemia- Propionic acidemia is an autosomal recessive disorder caused by loss-of-function mutations in PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB), resulting in the lossof enzymatic activity of the mitochondrial complex PCC MedDRA version: 21.0;Level: LLT;Classification code 10080615;Term: Propionic acidemia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: mRNA-3927 INN or Proposed INN: N/A Other descriptive name: CX-016492 INN or Proposed INN: NA Other descriptive name: CX-017950 | ModernaTX, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | United States;Canada;United Kingdom | ||
| 2 | NCT04159103 (ClinicalTrials.gov) | March 2020 | 7/11/2019 | Open Label Study of mRNA-3927 in Patients With Propionic Acidemia | A Global, Phase 1/2, Open-label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia | Propionic Acidemia | Biological: mRNA-3927 | ModernaTX, Inc. | NULL | Not yet recruiting | 1 Year | N/A | All | 46 | Phase 1;Phase 2 | NULL |